Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Share-based Compensation (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Share-based Compensation data on record, last reported at $10.1 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 7.1% year-over-year to $10.1 million; the TTM value through Dec 2025 reached $40.4 million, down 3.27%, while the annual FY2025 figure was $40.4 million, 3.27% down from the prior year.
  • Share-based Compensation reached $10.1 million in Q4 2025 per ARQT's latest filing, roughly flat from $10.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $12.5 million in Q2 2024 and bottomed at $4.3 million in Q2 2021.
  • Average Share-based Compensation over 5 years is $8.9 million, with a median of $9.4 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: surged 758.89% in 2021, then decreased 23.17% in 2022.
  • A 5-year view of Share-based Compensation shows it stood at $5.7 million in 2021, then soared by 62.93% to $9.3 million in 2022, then dropped by 5.47% to $8.8 million in 2023, then grew by 7.26% to $9.4 million in 2024, then rose by 7.1% to $10.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $10.1 million in Q4 2025, $10.0 million in Q3 2025, and $10.5 million in Q2 2025.